Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

814

LikeLikedUnlike

Episodes 1-15 of 126

MinuteCE®
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 credits 2 episodes
Chemotherapy Strategies for Metastatic PDAC
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 program credits
Diagnosis and Management of Metastatic PDAC
MinuteCE®
Diagnosis and Management of Metastatic PDAC
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 program credits
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Project Oncology®
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Matthew Matasar, MD
  Peer
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
Project Oncology®
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Sairah Ahmed, MD
  Peer
- Caron A. Jacobson, MD
  Peer
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Project Oncology®
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Paolo Tarantino, MD
  Peer
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
On the Frontlines of Non-Small Cell Lung Cancer
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
- Jacob Sands, MD
  Peer
- Julia Rotow, MD
  Peer
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Project Oncology®
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
- Tara Graff, DO, MS
  Peer
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Project Oncology®
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Project Oncology®
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
- Adrienne Waks, MD
  Peer
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
On the Frontlines of Non-Small Cell Lung Cancer
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Laura Alder, MD
  Peer
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Project Oncology®
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
- Ben Park, MD, PhD
  Peer
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
On the Frontlines of Non-Small Cell Lung Cancer
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
- Jacob Sands, MD
  Peer
- Aaron Lisberg, MD
  Peer
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
On the Frontlines of Non-Small Cell Lung Cancer
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
- Jacob Sands, MD
  Peer
- Aaron Lisberg, MD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended